PL1924585T3 - Nowa krystaliczna postać pochodnej pirydazyno[4,5-B]indolu - Google Patents

Nowa krystaliczna postać pochodnej pirydazyno[4,5-B]indolu

Info

Publication number
PL1924585T3
PL1924585T3 PL06813757T PL06813757T PL1924585T3 PL 1924585 T3 PL1924585 T3 PL 1924585T3 PL 06813757 T PL06813757 T PL 06813757T PL 06813757 T PL06813757 T PL 06813757T PL 1924585 T3 PL1924585 T3 PL 1924585T3
Authority
PL
Poland
Prior art keywords
pyridazino
crystalline form
novel crystalline
indole derivative
indole
Prior art date
Application number
PL06813757T
Other languages
English (en)
Inventor
William L Rocco
John D Higgins
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1924585(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of PL1924585T3 publication Critical patent/PL1924585T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL06813757T 2005-08-29 2006-08-24 Nowa krystaliczna postać pochodnej pirydazyno[4,5-B]indolu PL1924585T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29
PCT/US2006/033254 WO2007027525A1 (en) 2005-08-29 2006-08-24 Novel crystalline form of a pyridazino [4 , 5-b] indole derivative
EP06813757A EP1924585B1 (en) 2005-08-29 2006-08-24 Novel crystalline form of a pyridazino [4 , 5-b] indole derivative

Publications (1)

Publication Number Publication Date
PL1924585T3 true PL1924585T3 (pl) 2012-08-31

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06813757T PL1924585T3 (pl) 2005-08-29 2006-08-24 Nowa krystaliczna postać pochodnej pirydazyno[4,5-B]indolu

Country Status (32)

Country Link
US (1) US7683062B2 (pl)
EP (1) EP1924585B1 (pl)
JP (1) JP5063600B2 (pl)
KR (2) KR20130087059A (pl)
CN (1) CN101253176B (pl)
AR (1) AR057099A1 (pl)
AT (1) ATE531717T1 (pl)
AU (1) AU2006285142B2 (pl)
BR (1) BRPI0615259A2 (pl)
CA (1) CA2619284C (pl)
CR (1) CR9723A (pl)
CY (1) CY1112317T1 (pl)
DK (1) DK1924585T3 (pl)
EA (1) EA014164B1 (pl)
EC (1) ECSP088209A (pl)
ES (1) ES2375841T3 (pl)
HK (1) HK1123794A1 (pl)
HR (1) HRP20120073T1 (pl)
IL (1) IL189276A (pl)
MA (1) MA30000B1 (pl)
NO (1) NO20081365L (pl)
NZ (1) NZ566087A (pl)
PL (1) PL1924585T3 (pl)
PT (1) PT1924585E (pl)
RS (1) RS52318B (pl)
SI (1) SI1924585T1 (pl)
TN (1) TNSN08059A1 (pl)
TW (1) TW200813060A (pl)
UA (1) UA91716C2 (pl)
UY (1) UY29771A1 (pl)
WO (1) WO2007027525A1 (pl)
ZA (1) ZA200801890B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065018A2 (en) * 2003-11-17 2005-07-21 Merck Eprova Ag Crystalline forms of (6r) -l-erythro-tetrahydrobiopterin dihydrochloride
EP1776365B1 (en) * 2004-06-02 2011-08-03 Sandoz Ag Meropenem intermediate in crystalline form
KR101314158B1 (ko) * 2005-09-21 2013-10-04 4에스체 악티엔게젤샤프트 히스톤 탈아세틸 효소 억제제로서의 설포닐피롤 염산염
EA201001799A1 (ru) * 2005-10-31 2011-06-30 Янссен Фармацевтика Н.В. Новые способы получения пиперазинильных и диазепанильных производных бензамида
JP5318757B2 (ja) * 2006-06-16 2013-10-16 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形
NZ589053A (en) * 2006-10-27 2012-03-30 Signal Pharm Llc Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
WO2010021905A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-n, n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4h-pyridazin0[4,5-b]indole-1-acetamide
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
MX2013002421A (es) * 2010-09-01 2013-05-17 Arena Pharm Inc Sales no hidroscopicas de agonistas de 5-ht2c.
JP2014530805A (ja) * 2011-09-30 2014-11-20 スンシネ ルアケ プハルマ カンパニー リミテッド アジルサルタンの結晶形並びにその製造及び使用
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种***共晶物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
WO2005034999A2 (en) 2003-10-10 2005-04-21 Bvm Holding Co. Composition comprising association complex of a pharmaceutical and a poloxamer

Also Published As

Publication number Publication date
NO20081365L (no) 2008-04-03
WO2007027525A1 (en) 2007-03-08
PT1924585E (pt) 2012-01-19
UY29771A1 (es) 2007-03-30
CY1112317T1 (el) 2015-12-09
ECSP088209A (es) 2008-06-30
JP5063600B2 (ja) 2012-10-31
JP2009506116A (ja) 2009-02-12
CR9723A (es) 2008-06-18
ES2375841T3 (es) 2012-03-06
AU2006285142B2 (en) 2012-06-14
BRPI0615259A2 (pt) 2011-05-17
KR20080050577A (ko) 2008-06-09
MA30000B1 (fr) 2008-12-01
EA014164B1 (ru) 2010-10-29
CA2619284C (en) 2014-04-29
EP1924585A1 (en) 2008-05-28
EP1924585B1 (en) 2011-11-02
IL189276A (en) 2012-07-31
EA200800716A1 (ru) 2008-08-29
HK1123794A1 (en) 2009-06-26
NZ566087A (en) 2011-03-31
DK1924585T3 (da) 2012-02-27
AR057099A1 (es) 2007-11-14
RS52318B (en) 2012-12-31
CN101253176B (zh) 2012-04-18
AU2006285142A1 (en) 2007-03-08
US7683062B2 (en) 2010-03-23
SI1924585T1 (sl) 2012-09-28
TW200813060A (en) 2008-03-16
KR20130087059A (ko) 2013-08-05
UA91716C2 (ru) 2010-08-25
IL189276A0 (en) 2008-08-07
US20080139569A1 (en) 2008-06-12
ATE531717T1 (de) 2011-11-15
HRP20120073T1 (hr) 2012-07-31
ZA200801890B (en) 2009-11-25
CN101253176A (zh) 2008-08-27
TNSN08059A1 (en) 2009-07-14
CA2619284A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
HK1123794A1 (en) Novel crystalline form of a pyridazino [4,5-b] indole derivative
EG25765A (en) Pyrido [2,3-B] pyrazine derivatives useful as herbicidal compounds
HUS1200009I1 (hu) Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok
ZA200800785B (en) Novel benzo [D] [1,3]-dioxol derivatives
HK1094800A1 (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino [4,5-c]pyrrole
ZA200805354B (en) Aryl-isoxazol-4-yl-imidazo[1,5-A]pyridine derivatives
AU2008313773A8 (en) Imidazo [1, 2-A] pyridine derivatives useful as ALK inhibitors
IL215686A (en) A process for making pure enzymes
IL189667A0 (en) 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
EP1809613A4 (en) PROCESSES FOR PRODUCING 2,6-DIARYLE PIPERIDINE DERIVATIVES
EP1893625A4 (en) PROCESS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES
HK1122797A1 (en) Derivatives of pyrido
HK1108580A1 (en) A process for the preparation of [1,4,5]-oxadiazepine derivatives
IL190729A0 (en) Methods for preparing glutamic acid derivatives
IL187441A0 (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid
EP1847546A4 (en) IMIDAZOPYRIDINE DERIVATIVE
IL191546A0 (en) Process for the preparation of purified crystalline cci-779
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
IL186174A0 (en) A process for the preparation of 6-0-methyl erythromycin a derivative
IL187326A0 (en) Crystalline form of benzazepinium maleate derivative
IL189370A0 (en) PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND
PT1600446E (pt) Novos derivados de 3,3-dimetil-5-ciano-benzoxepina úteis para a preparação de derivados de 5-formil-benzoxepina